➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: May 30, 2020

DrugPatentWatch Database Preview

Patent: 9,919,057

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,919,057
Title:Compounds comprising self-immolative group
Abstract: Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
Inventor(s): Kim; Yong Zu (Daejeon, KR), Park; Tae Kyo (Daejeon, KR), Woo; Sung Ho (Daejeon, KR), Kim; Sun Young (Daejeon, KR), Cho; Jong Un (Daejeon, KR), Jung; Doo Hwan (Daejeon, KR), Yang; Jeon (Daejeon, KR), Min; Ji Young (Daejeon, KR), Lee; Hyang Sook (Daejeon, KR), Park; Yun Hee (Daejeon, KR), Ryu; Jeong Hee (Daejeon, KR), Oh; Kyu Man (Daejeon, KR), Oh; Yeong Soo (Daejeon, KR), Chae; Jeiwook (Daejeon, KR), Song; Ho Young (Daejeon, KR), Chung; Chul-Woong (Daejeon, KR)
Assignee: LegoChem Biosciences, Inc. (Daejeon, KR)
Application Number:14/865,778
Patent Claims:see list of patent claims

Details for Patent 9,919,057

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline NUCALA mepolizumab INJECTABLE;SUBCUTANEOUS 761122 001 2019-06-06   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.